Sedation & Preanesthetic - Feline
®
DEXDOMITOR Sedation
& Analgesic Dosing Chart - FELINE
DEXDOMITOR
(dexmedetomidine) - 0.5 mg/mL
Consider
Body Surface
Area (BSA)
dosing with
DEXDOMITOR
in some cats
IM Administration
The FDA-approved DEXDOMITOR dose for cats is based on body weight
Since there is a small range in feline body weight, a 40 mcg/kg feline dose
was approved for DEXDOMITOR. However, BSA dosing may be an
important consideration for cats weighing less than 4.5 kg.
BSA is a better indicator of metabolic mass than body weight1,2
40 mcg/kg
Body Weight
BSA is the measured or calculated body surface of an animal
BSA dosing requires the accurate determination of an animal’s body weight
Clinically, this is particularly critical for animals of smaller body weight
mL
lb
kg
mcg/kg
2-4
1-2
40
0.1
4.1-7
2.1-3
40
0.2
7.1-9
3.1-4
40
0.3
9.1-13
4.1-6
40
0.4
13.1-15
6.1-7
40
0.5
15.1-18
7.1-8
40
0.6
18.1-22
8.1-10
40
0.7
Body Surface Area dosing may be a consideration
for cats of smaller body weight
Interactive
Dosing
Calculator at
DexdomitorUSA.com
Feline DEXDOMITOR Dosing
Feline DEXDOMITOR Dosing
60
BSA Dosing
Bodyweight Dosing (label dose)
Dose (mcg/kg)
50
40
For assistance, call Pfizer Animal Health at 1-800-366-5288.
30
20
10
0
kg 2
lb 4.4
Dose (mcg/kg)
80
3
6.6
4.5
4
5
8.8 11.0
6
7
8
9
10
13.2 15.4 17.6 19.8 22.0
Body Weight (kg and lb)
60
40
20
kg 4
lb
8.8
8
12
16
20
24
28
32
36
40
44
17.6
26.5
35.3
44.1
52.9
61.7
70.6
79.4
88.2
97.0
48
52
56
60
64
68
105.8 114.6 123.5 132.3 141.1 149.9
Body Weight (kg and lb)
This chart is a representation of BSA dosing as compared to the FDA-approved feline dose.
References: 1) Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer
Res. 1958;18:853-856. 2) Singer D. Size relationship of metabolic rate: Oxygen availability as the “missing link” between
structure and function? Thermochimica Acta. 2006;446(1-2):20-28.
176420_chart.indd 1
Important Safety Information
Do not use DEXDOMITOR in dogs or cats with cardiovascular disease, respiratory disorders,
liver or kidney diseases, or in conditions of shock, severe debilitation, or stress due to extreme
heat, cold, or fatigue. DEXDOMITOR should not be administered in the presence of preexisting
hypotension, hypoxia, or bradycardia. As with all 2-adrenoceptor agonists, the potential for
isolated cases of hypersensitivity, including paradoxical response (excitation), exists. The use of
DEXDOMITOR as a preanesthetic in dogs and cats significantly reduces the amount of induction
and maintenance anesthetic requirements. Careful patient monitoring is necessary to avoid
anesthetic overdose. Arrhythmias, bradycardia, apnea, emesis, convulsions, hypersalivation
may occur with DEXDOMITOR use. Severe dyspnea and respiratory crackles due to acute or
delayed pulmonary edema could develop in cats. DEXDOMITOR has not been evaluated for use
in breeding, pregnant, or lactating dogs or cats; in dogs younger than 16 weeks of age or in cats
younger than 12 weeks of age; in geriatric dogs or cats. For more safety information, refer to the
accompanying full prescribing information.
DEXDOMITOR is a trademark owned by Orion Corporation and Orion Pharma. This product is developed and manufactured by Orion Corporation, Orion Pharma Finland and
distributed by Pfizer Inc. ©2010 Pfizer Inc. All rights reserved. DEX0610002
8/25/10 2:05 PM